App-Quantinova.ai

Phase I dose-escalation study of an oral administration of the pan-histonedeacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.

Arnaud Scherpereel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Abexinostat

Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.

Rahul Raj Aggarwal - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Abexinostat

Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi).

Bernhard Hauns - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Resminostat

Population PK/PD analysis of the pan-HDAC inhibitor resminostat.

Roland Baumgartner - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Resminostat

Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors.

Ding Wang - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Diclofenac

Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.

Veronique Dieras - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.

Jennifer Robinson Diamond - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment.

Elisabeth Rouits - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function.

Antoinette R. Tan - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Eribulin

Comparison of chemosensitivity testing of CETCs and spheroids in cancer patients with solid tumors.

Katharina Pachmann - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

David Fairman - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Durvalumab

The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects.

Masaya Tachibana - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tivantinib

Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.

Anu Radha Neerukonda - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Temsirolimus

Evaluation indel TYMS gene polymorphism in association with response regarding the use of fluoropyrimidines in patients with neoplasms of the gastrointestinal tract in the Brazilian Amazon.

Danielle Costa - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.

Mark N. Stein - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ramucirumab

Intake of alternative medicine during cancer treatment and possible drug interactions.

Elena Tenti - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphisms associated with toxicity in patients treated with flourpyrimidines in northern Brazil.

Williams Fernandes Barra - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Absolute bioavailability, mass balance, elimination route, and metabolite profile of the selective oral MEK1/2 inhibitor pimasertib in cancer patients.

Giorgio Massimini - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pimasertib

TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.

Desamparados Roda - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.

Richard D. Kim - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BAY 80-6946

Filters

41730 Abstracts